PharmaCyte Biotech, Inc. PMCB
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- -57.14%
- 1 year
- -66.63%
- Open
- 0.31
- Prev close
- 0.3021
- Mkt cap
- 3.33M
- Vol
- 40.84K
- Avg vol
- 185.15K
- EPS
- -2.31
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.31
- High
- 0.32
- Forward P/E
- -4.21
- Beta
- -0.20
- Short ratio
- 1.09
- Inst. own
- 13.16%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.73
- 200-d avg
- 1.94
- 1y target
- 0.00
Key statistics
- Market cap
- 11.15M
- Enterprise value
- -14.09M
- Trailing P/E
- 1.82
- Forward P/E
- -4.21
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.47
- EPS (TTM)
- 0.88
- Beta
- -0.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 3.13M
- Total cash
- 32.64M
- Total debt
- 0
- Return on equity
- 47.88%
- Shares outstanding
- 6.97M
- Short % of float
- 1.18%
- 50-day average
- 1.73
- 200-day average
- 1.94
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 13, 2024 | Oct 1, 2024 | 0.00 | -0.29 | — | — |
| Sep 16, 2024 | Jul 1, 2024 | 0.00 | 0.14 | — | — |
| Aug 13, 2024 | Apr 1, 2024 | 0.00 | -0.85 | — | — |
| Mar 18, 2024 | Jan 1, 2024 | 0.00 | -0.65 | — | — |
| Dec 15, 2023 | Oct 1, 2023 | 0.00 | -0.64 | — | — |
| Sep 18, 2023 | Jul 1, 2023 | 0.00 | -0.28 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2021 | HC Wainwright & Co. | init | — | Neutral |
About PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- pharmacyte.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on PMCB — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.01% | 168,200 | 269.12K | Sep 29, 2024 |
| Vanguard Group Inc | 0.01% | 192,387 | 307.82K | Sep 29, 2024 |
| K2 Principal Fund, L.P. | 0.01% | 209,266 | 334.82K | Sep 29, 2024 |
| Equitec Proprietary Markets LLC | 0.00% | 82,727 | 132.36K | Sep 29, 2024 |
| Dimensional Fund Advisors LP | 0.00% | 27,601 | 44.16K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.00% | 49,700 | 79.52K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Schwab Capital Trust-Total Stock Market Index Fund | 0.00% | 5,947 | 9.52K | Jul 30, 2024 |
| DFA U.S. Targeted Value Portfolio | 0.00% | 2,009 | 3.21K | Jul 30, 2024 |
| Dimensional ETF Tr-Dimensional U.S. Core Equity 2 ETF | 0.00% | 11,506 | 18.41K | Jul 30, 2024 |
| Dimensional ETF Tr-Dimensional U.S. Targeted Value ETF | 0.00% | 8,707 | 13.93K | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 0.00% | 117,468 | 187.95K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 74,919 | 119.87K | Sep 29, 2024 |